News

ADHD link to obesity may involve stimulant use

View on the News

Study offers insights to stimulant use with caveats

Dr. L. Eugene Arnold, Dr. Laurence L. Greenhill, and James M. Swanson, Ph.D., comment: This article provides a great example of the benefits of electronic health records, which provided access to a large sample size (approximately 15,000 with ADHD and about 11,000 treated with stimulants). It also addresses a very important question: Can a side effect of stimulants produce a secondary benefit by reducing obesity in ADHD individuals? And it provides a clear answer: No, the initial effect of stimulants is to reduce BMI in childhood, but the effect in adolescence is the opposite.

However, some technical issues also should be noted to put the basic findings into context. First, these effects on BMI do not represent a new pattern unique to ADHD; in the 1960s when these drugs were used often by non-ADHD adults for weight control, apparently initial weight loss later turned into weight gain.Next, the modest differences in BMI for untreated (about 25.5 kg/m2) and treated (about 26.5 kg/m2) ADHD cases were projected by regression analyses at about 17 years of age, but at the ages when most observations of BMI were obtained (8-12 years), the differences were not clinically or statistically significant.

In addition, the differences in BMI trajectories attributed to differences in treatment could actually be due to differences in maturation, which could be evaluated by structural analysis with a mathematical model of human growth.Surprisingly, this sophisticated approach revealed early maturation in untreated ADHD children, which may masquerade as and be interpreted as growth rebound.Finally, initial growth suppression when stimulant medication is initiated in childhood is well established, but "catchup" growth is complicated: Longitudinal data from the Multimodal Treatment Study of Children With ADHD questioned whether catch-up in height occurs and suggested rebound in weight but not height.

This study has practical implications: Clinicians prescribing stimulant medication should keep longitudinal measures of growth of their patients to monitor the trajectory of BMI over time. Along with other studies, additional implications are that patients, parents, and clinicians need not worry about excessive weight loss with stimulants, clinicians should advise patients who are stopping stimulants about the danger of rebound obesity, and all patients should be educated about a balanced diet and coached in adjusting caloric density to appetite.

Dr. L. Eugene Arnold is professor emeritus of psychiatry at Ohio State University, Columbus, and has 40 years’ experience in child psychiatric research, including the multisite Multimodal Treatment Study of Children With ADHD, for which he received the National Institutes of Health Director’s Award and continues as executive secretary and current chair of the steering committee. Dr. Laurence L. Greenhill is the Ruane Professor of Clinical Child and Adolescent Psychiatry at Columbia University, New York, and has had a career-long interest in studying the long-term effects of stimulant medication on children with ADHD. James M. Swanson, Ph.D., is professor of psychiatry at Florida International University and professor emeritus of pediatrics at the University of California, Irvine, and his recent research has focused on assessments of long-term outcomes of individuals diagnosed with ADHD in childhood. Dr. Arnold has received research funding from Curemark, Forest, Lilly, and others, and he has consulted or been on advisory boards for Neuropharm, Novartis, Noven, and others. Dr. Greenhill has received grant support from Shire and Rhodes, and has served as a member of the scientific advisory board of BioBDX. Dr. Swanson has served on the advisory board of Noven Pharmaceuticals, and provided expert testimony for Janssen-Ortho on pharmacokinetic and pharmacodynamics properties of methylphenidate.


 

FROM PEDIATRICS

The link between attention-deficit/hyperactivity disorder and later obesity may exist for both children with ADHD treated or not treated with stimulants, according to a study published online in Pediatrics March 17.

A longitudinal analysis of electronic health records for 163,820 Pennsylvania children, aged 3-18 years and 91% of whom were white, revealed variations in body mass index (BMI) trajectories for children with untreated ADHD, with ADHD and taking stimulant medications, and without ADHD, reported Dr. Brian Schwartz of the Johns Hopkins Bloomberg School of Public Health, Baltimore, and his colleagues. Among the children, 8.4% were diagnosed with ADHD, 6.8% had been prescribed stimulants, and 9.5% had either an ADHD diagnosis or a stimulant prescription (Pediatrics 2014 [doi:10.1542/peds.2013-3427]).

Dr. Schwartz’s team analyzed modeled untransformed BMI values instead of BMI z scores because the former "yields estimates that are more interpretable, precise, and sensitive to factors that alter change," they wrote. The researchers identified a curvilinear average trajectory of BMI increasing with age, with girls having higher BMIs than boys at all ages and black children diverging by age 5 and continuing to widen with age.

Compared with children who neither had ADHD nor were taking stimulants, children with ADHD who were not taking stimulants showed more rapid BMI growth after age 10 years. Children prescribed stimulants but lacking an ADHD diagnosis had a lower average BMI trajectory than did the controls (neither ADHD nor stimulant use).

Meanwhile, those with ADHD and taking stimulants had slower BMI growth in early childhood but later "rebounded," ending with BMIs in late adolescence that exceeded those of controls – especially if they started taking stimulants at a younger age and took them for longer. "The earlier stimulants were ordered, the earlier and stronger that BMI growth ‘rebounded’ and eventually exceeded values in controls," the researchers wrote.

The findings suggest that stimulant use, rather than ADHD itself, is most strongly associated with growth trajectories in childhood, early BMI rebound, and later obesity," Dr. Schwartz’s team wrote. The researchers discussed possible ways that stimulants might affect usual growth patterns and noted that "behavioral therapy, specifically parent training, can be effective for ADHD management and has no known BMI rebound effect."

The study was funded by the National Institutes of Health. No disclosures were reported.

Recommended Reading

The politics of food addiction: Who wins, who 'loses'
MDedge Family Medicine
Too much dietary sugar raises CVD mortality
MDedge Family Medicine
NASH liver transplant mortality differs from non-NASH
MDedge Family Medicine
Obesity at age 20 associated with increased risk of multiple sclerosis
MDedge Family Medicine
The future of obesity treatments could include endoscopically placed devices
MDedge Family Medicine
Obesity prevalence steady between 2003 and 2012
MDedge Family Medicine
Obesity a driving factor in stillbirth
MDedge Family Medicine
Obesity does not interfere with accuracy of noninvasive preterm birth monitoring
MDedge Family Medicine
Obesity-hunger paradox prevalent in low-income cancer survivors
MDedge Family Medicine
Can coffee reduce weight?
MDedge Family Medicine